DLRC Launches Regulatory Spark to Give Early-Stage Innovators an Investor-Ready Route to Clinic
New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact.
DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.
Regulatory Spark is designed to help founder-led biotech companies, scientific founders, academic spinouts, and tech transfer teams understand their likely route to the clinic before key funding, development, or investor decisions are made. In just 1 to 2 weeks, innovators receive a practical regulatory toolkit covering high-level product classification, a path-to-clinic roadmap, data requirements, the regulatory risks that matter most, and an investor-ready summary.
The greatest development risks often arise at the very beginning. Founders can make pivotal decisions on product classification, CMC and non-clinical development before seeking regulatory advice, only to discover later that course corrections are costly, time-consuming and disruptive. Yet the strategic regulatory support needed to avoid these pitfalls is often priced well beyond early-stage budgets, creating a gap between when expert guidance is most valuable and when companies can realistically afford it.
Regulatory Spark closes that gap. It packages senior, multi-region regulatory insight into a transparent, founder-facing product, helping innovators answer the questions investors most often ask: “What is your regulatory pathway?” and “What data do you need?”
Key features of the Regulatory Spark service include:
- Product Classification & Pathway: A high-level assessment of how the asset is likely to be regulated (drug, biologic or ATMP).
- Path-to-Clinic Roadmap: A simple visual roadmap from the current position through to CTA / IND readiness, with indicative timelines.
- Top Regulatory Risks: An outline of the regulatory and development risks that matter most.
- Data Requirements: A high-level overview of the non-clinical and CMC data likely to be needed before first-in-human studies.
- Investor-Ready Summary: A concise summary that can be shared with investors, accelerators and grant bodies.
- Founder Discussion: A 60-minute review call with a senior DLRC consultant to walk through the roadmap, answer questions and agree on next steps.
As programmes develop, Regulatory Spark offers a clear upgrade path into The Regulatory Catalyst and wider DLRC support for deeper preclinical, CMC, clinical development strategy and CTA or IND planning.
DLRC’s approach is practical and outcome-focused. It helps early-stage teams de-risk before they spend, raise with credibility, and move at founder speed, turning early-stage uncertainty into investor confidence.
Discover more about the new service offering here.
Hear from DLRC’s Chief Regulatory Officer, Wafa Bouaziz:
“Regulators recommend early engagement with regulatory consulting firms; nine out of ten biotech start-ups never reach the market; Regulatory Spark gives founders senior, multi-region regulatory direction at a seed-stage price and in a seed-stage timeframe. This will also give investors’ confidence in the regulatory route to clinic.”
About DLRC
DLRC is an award-winning consultancy team of >80 highly qualified and experienced professionals operating from offices in the UK, Germany, and the US. With a deep commitment to excellence, we are dedicated to helping clients navigate the complex regulatory, HTA and market access landscape of the life science industry. We develop and execute innovative phase-appropriate strategies that connect regulatory planning, evidence generation, and access considerations, providing comprehensive support from early development to post-licensing activities for medicinal products and medical devices.
Our team brings together experts in nonclinical, CMC, and clinical development, as well as HTA and market access, with extensive experience of pharmaceutical industry, product development and regulatory agencies. We have diligently served companies of all sizes and backgrounds across a broad range of therapeutic areas, product types and development stages.
DLRC Group is a Certified B CorporationTM (B CorpTM), demonstrating that we meet high standards across our entire operation, including governance, workers, environment, customers, and community.
Contact Information
For media inquiries or additional information, please email [email protected]
Website: www.dlrcgroup.com
